New drug combo aims to spare kidneys in High-Risk urinary tract cancer

NCT ID NCT05912816

Recruiting now Disease control Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests two drugs—RC48 and Tislelizumab—given before kidney-sparing surgery in 20 people with high-risk upper tract urothelial carcinoma. The goal is to control the cancer while preserving the kidney, avoiding complete removal. Researchers will track how long patients stay cancer-free without losing the kidney.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RC48 (disitamab vedotin) combined with tislelizumab
What this could lead to: If successful, this approach could allow patients with high-risk upper tract cancer to keep their kidney while controlling the disease, avoiding complete kidney removal.
What could go wrong: This is a small, early-phase trial with only 20 participants. The combination therapy may cause side effects, and it is not yet proven to be better than standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER-2 ADC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal pelvis/ureter urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER-2 ADC KIDNEY PRESERVATION PD-1ANTIBODY UPPER URINARY TRACT UROTHELIAL CARCINOMA

Contacts and locations

Locations

Ethics Committee of Shanghai Renji Hospital
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.